The Addario Lung Cancer Medical Institute (ALCMI) is a non-profit international consortium comprised of over 25 of the world's premier oncology research institutions. We fund and support investigator-led lung cancer clinical trials.
Addario Lung Cancer Medical Institute (ALCMI)
Loading...
Oregon State University researchers have made a compelling dual-target discovery. They have developed a single therapy that simultaneously targets lung cancer and cancer cachexia. #lungcancer
news.oregonstate.edu/news/researc...
Researchers at Roswell Park Comprehensive Cancer Center and Winship Cancer Institute of Emory University have developed an AI-powered tool that can predict treatment response in extensive-stage small cell lung cancer before a single dose of chemotherapy is given. #lungcancer
New research is challenging the idea of how old is too old for surgery in early-stage lung cancer. #lungcancer
www.mountsinai.org/about/newsro...
Dr. Lovly and Dr. Lee examined how risk-benefit profiles should drive frontline treatment selection, weighing efficacy, toxicity, and patient-specific factors when choosing between osimertinib monotherapy and combination approaches. #lungcancer
Congrats to the researchers at the ALCMI consortium member, Mass General Brigham Cancer Institute. They have shown that pralsetinib can extend median overall survival for advanced RET fusion-positive NSCLC from roughly 4–11 months to 44 months. #lungcancer
www.massgeneralbrigham.org/en/about/new...
EGFR-mutated NSCLC is not just another subtype of lung cancer — it is a distinct molecular entity that demands a fundamentally different treatment strategy. #lungcancer
www.cancernetwork.com/view/egfr-bi...
Congrats to TRIANA Biomedicines! The company has earned FDA Fast Track designation for TRI-611, a first-in-class molecular glue degrader targeting ALK fusion proteins in ALK-positive non-small cell lung cancer. #lungcancer
www.cancernetwork.com/view/novel-s...
New trial alert! Memorial Sloan Kettering Cancer Center has launched a new investigator-initiated Phase 2 trial evaluating BIO 300 Oral Suspension in patients with non-small cell lung cancer and concomitant interstitial lung disease. #lungcancer
finance.yahoo.com/sectors/heal...
A new study found that incidental findings flagged during low-dose CT screening could be signs of other non-lung, undiagnosed cancers. #lungcancer
jamanetwork.com/journals/jam...
Updated data from the phase 2 PALOMA-2 trial point to a meaningful advance in first-line treatment for patients with EGFR-mutated metastatic NSCLC. #lungcancer
www.onclive.com/view/dr-gira...
Addario Lung Cancer Medical Institute (ALCMI)
Addario Lung Cancer Medical Institute (ALCMI)
Addario Lung Cancer Medical Institute (ALCMI)
Addario Lung Cancer Medical Institute (ALCMI)
Addario Lung Cancer Medical Institute (ALCMI)
Addario Lung Cancer Medical Institute (ALCMI)
Addario Lung Cancer Medical Institute (ALCMI)
Addario Lung Cancer Medical Institute (ALCMI)
Addario Lung Cancer Medical Institute (ALCMI)
Addario Lung Cancer Medical Institute (ALCMI)
news.oregonstate.edu
PORTLAND, Ore. – Researchers at Oregon State University have developed a technique for simultaneously treating lung cancer and a serious muscle-wasting condition that often accompanies it. The study,…
In this segment, Alexander Spira, MD, PhD, engages Natalie Vokes, MD, in a discussion on the distinct biology of EGFR-mutated non–small cell lung cancer and how it informs treatment decisions in the…
www.cancernetwork.com
medicalxpress.com
Results of a new study conclude that a pathology tool powered by artificial intelligence can predict whether a patient with extensive-stage small cell lung cancer will respond to platinum-based…
This cohort study examines the association between significant incidental findings on lung cancer screening in the National Lung Screening Trial and the diagnosis of an extrapulmonary cancer within 1…
Investigators are currently evaluating treatment with TRI-611 among patients with ALK-positive non–small cell lung cancer in a phase 1/2 trial.
MINNEAPOLIS, March 31, 2026--Investigator-initiated at a leading cancer center will provide explore BIO 300's potential.
finance.yahoo.com
Nicolas Girard, MD, PhD, discusses updated data from the phase 2 PALOMA-2 trial (NCT05498428) that were presented at the 2026 European Lung Cancer Congress.
